AGGN: Attention-based glioma grading network with multi-scale feature extraction and multi-modal information fusion

Computers in Biology and Medicine, Journal Year: 2022, Volume and Issue: 152, P. 106457 - 106457

Published: Dec. 21, 2022

Language: Английский

---

Application of radiomics-based multiomics combinations in the tumor microenvironment and cancer prognosis

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Sept. 6, 2023

Abstract The advent of immunotherapy, a groundbreaking advancement in cancer treatment, has given rise to the prominence tumor microenvironment (TME) as critical area research. clinical implications an improved understanding TME are significant and far-reaching. Radiomics been increasingly utilized comprehensive assessment prognosis. Similarly, pathomics, which is based on pathological images, can offer additional insights into panoramic view microscopic information tumors. combination pathomics radiomics revolutionized concept “digital biopsy”. As genomics transcriptomics continue evolve, integrating with genomic transcriptomic datasets further heterogeneity establish correlations biological significance. Therefore, synergistic analysis digital image features (radiomics, pathomics) genetic phenotypes (genomics) comprehensively decode characterize well predict This review presents summary research important biomarkers for predicting TME, emphasizing interplay between radiomics, genomics, transcriptomics, application multiomics decoding Finally, we discuss challenges opportunities In conclusion, this highlights crucial role associations combined promising direction substantial significance value evaluation prognosis assessment.

Language: Английский

---

PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area

Cancers, Journal Year: 2022, Volume and Issue: 14(5), P. 1103 - 1103

Published: Feb. 22, 2022

PET plays an increasingly important role in the management of brain tumors. This review outlines currently available radiotracers and their respective indications. It specifically focuses on 18F-FDG, amino acid somatostatin receptor radiotracers, for imaging gliomas, meningiomas, primary central nervous system lymphomas as well metastases. Recent advances radiopharmaceuticals, image analyses translational applications to therapy are also discussed. The objective this is provide a comprehensive overview imaging's potential neuro-oncology adjunct MRI all medical professionals implicated tumor diagnosis care.

Language: Английский

---

Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group

Neuro-Oncology, Journal Year: 2022, Volume and Issue: 24(11), P. 1815 - 1826

Published: June 8, 2022

Many studies in patients with brain tumors evaluating innovative PET tracers have been published recent years, and the initial results are promising. Here, Response Assessment Neuro-Oncology (RANO) working group provides an overview of literature on novel investigational for tumor patients. Furthermore, newer indications more established evaluation glucose metabolism, amino acid transport, hypoxia, cell proliferation, others also discussed. Based preliminary findings, these should be further evaluated considering their promising potential. In particular, probes imaging translocator protein somatostatin receptor overexpression as well immune system reactions appear to additional clinical value delineation therapy monitoring. Progress developing radiotracers may contribute improving diagnostics advancing translational research.

Language: Английский

---

Potential of TSPO radioligands: Bridging brain tumor diagnostics to the peripheries

Biochimie, Journal Year: 2024, Volume and Issue: 224, P. 114 - 119

Published: May 9, 2024

Translocator protein (TSPO) is involved in several cellular mechanisms such as steroidogenesis, immunomodulation, cell proliferation and differentiation. Overexpressed neurodegenerative diseases brain cancer, TSPO radioligands have been developed over the last 20 years positron emission tomography (PET) imaging. Recently, extended beyond their initial application due to specific binding activated macrophages, making them a compelling biomarker for deciphering intricacies of tumor microenvironment (TME). In this review, we synthesized recent progress from evaluation TSPO-specific PET tracers various peripheral models highlighted hurdles limitations associated with heterogeneous uptake healthy tissue regions achieve clinical development radiotracer.

Language: Английский

---

Convenient PET-tracer production via SuFEx 18F-fluorination of nanomolar precursor amounts

European Journal of Medicinal Chemistry, Journal Year: 2022, Volume and Issue: 237, P. 114383 - 114383

Published: April 14, 2022

Language: Английский

---

TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 50(3), P. 859 - 869

Published: Nov. 4, 2022

Glioma patients, especially recurrent glioma, suffer from a poor prognosis. While advances to classify glioma on molecular level improved prognostication at initial diagnosis, markers prognosticate survival in the situation are still needed. As 18 kDa translocator protein (TSPO) was previously reported be associated with aggressive histopathological features, we correlated TSPO positron emission tomography (PET) signal using [18F]GE180 large cohort of patients their clinical outcome.In PET recurrence, parameters (e.g., SUVmax) as well other imaging features MRI volume, [18F]FET when available) were evaluated together patient characteristics (age, sex, Karnofsky-Performance score) and neuropathological (e.g. WHO 2021 grade, IDH-mutation status). Uni- multivariate Cox regression Kaplan-Meier analyses performed identify prognostic factors for post-recurrence (PRS) time treatment failure (TTF).Eighty-eight consecutive evaluated. tracer uptake tumor grade recurrence (p < 0.05), no significant differences IDH-wild-type versus IDH-mutant tumors. Within subgroup (n = 46), low SUVmax (median split, ≤ 1.60) had significantly longer PRS 41.6 vs. 25.3 months, p 0.031) TTF (32.2 vs 8.7 0.001). Also among glioblastoma 42), (≤ 1.89) not reached 8.2 0.002). remained an independent factor analysis including CNS IDH status, age. Tumor volume defined by or contrast-enhanced weakly uptake. Treatment regimen did differ median split subgroups.Our data suggest that can help even homogeneous subgroups may therefore serve valuable non-invasive biomarker individualized management.

Language: Английский

---

Feasibility of radiomic feature harmonization for pooling of [18F]FET or [18F]GE-180 PET images of gliomas

Zeitschrift für Medizinische Physik, Journal Year: 2023, Volume and Issue: 33(1), P. 91 - 102

Published: Jan. 28, 2023

Large datasets are required to ensure reliable non-invasive glioma assessment with radiomics-based machine learning methods. This can often only be achieved by pooling images from different centers. Moreover, trained models should perform high accuracy when applied data In this study, the impact of reconstruction settings and segmentation methods on radiomic features derived amino acid TSPO PET patients was examined. Additionally, ability model thus reduce feature differences investigated.[18F]FET [18F]GE-180 were acquired 19 patients. For each acquisition, 10 9 included emulate multicentric data. Statistical robustness measures calculated before after ComBat harmonization. Differences between due setting variations assessed using Friedman test, coefficient variation (CV) inter-rater reliability measures, including intraclass Spearman's rank correlation coefficients Fleiss' Kappa.According analyses, most (>60%) showed significant differences. Yet, CV indicated higher robustness. resulted in almost complete harmonization (>87%) according test little no improvement measures. more sensitive than [18F]FET features.According distributions could successfully aligned ComBat. However, depending settings, changes patient ranks observed for some not eliminated Thus, clinical utilization it is recommended exclude affected features.

Language: Английский

---

Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review

Expert Review of Anticancer Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 22

Published: April 5, 2025

The World Health Organization's 2021 classification of central nervous system neoplasms incorporated molecular and genetic features for classifying gliomas. Classification gliomas located in deep-seated structures became a clinical conundrum given the absence crucial pathological data. Advances noninvasive imaging modalities offered virtual biopsy as novel solution to this problem by identifying surrogate radiomic signatures. Liquid biopsies blood or cerebrospinal fluid provided another enormous opportunity genomic, metabolomic proteomic We summarize appraise current state evidence with regards liquid care patients PubMed, Embase Google Scholar were searched on 7/30/2024 relevant articles published after year 2013 English language. A large body preclinical preliminary suggests that is possible combined use multiple conjunction machine learning radiomics. Likewise, focused ultrasound may be valuable tool obtain genomic data regarding glioma minimally invasive manner. These will likely become an integral part future.

Language: Английский

---

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives

Cancers, Journal Year: 2023, Volume and Issue: 15(14), P. 3577 - 3577

Published: July 12, 2023

Advanced MRI methods and PET using radiolabelled amino acids provide valuable information, in addition to conventional MR imaging, for brain tumour diagnostics. These are particularly helpful challenging situations such as the differentiation of malignant processes from benign lesions, identification non-enhancing glioma subregions, progression treatment-related changes, early assessment responses anticancer therapy. The debate over which is preferable situation ongoing, has been addressed numerous studies. Currently, most radiology nuclear medicine departments perform these examinations independently each other, leading multiple patient. advent hybrid PET/MRI allowed a convergence methods, but date simultaneous imaging reached little relevance clinical neuro-oncology. This partly due limited availability scanners, also fact that second-line examination tumours. only required equivocal situations, spatial co-registration previous possible without disadvantage. A key factor benefit neuro-oncology multimodal approach provides decisive improvements diagnostics tumours compared with single modality. review focuses on studies investigating diagnostic value combined acid ‘advanced’ patients cerebral gliomas. Available suggest combination advanced improves grading histomolecular characterisation newly diagnosed Few data available concerning delineation extent. clear additive can be achieved regarding recurrence changes. Here, PET-guided evaluation seems helpful. In summary, there growing evidence achieve gliomas, offers optimal conditions.

Language: Английский

---